Differences between adult and pediatric septic shock

Minerva Anestesiologica

Volumn 77, Issue 10, 2011, Pages 986-992

  Aneja, R K ^a   Carcillo, J A ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Pediatrics; Sepsis; Septic; Shock

Indexed keywords

ACTIVATED PROTEIN C; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT DISEASE; AGE; CHILDHOOD DISEASE; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; HEART HEMODYNAMICS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; MULTIPLE ORGAN FAILURE; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PROTEIN FUNCTION; PROTHROMBIN TIME; REVIEW; SEPTIC SHOCK; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGING; CHILD; HEMODYNAMICS; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MULTIPLE ORGAN FAILURE; PROTEIN C; SHOCK, SEPTIC; THROMBOCYTOPENIA;

EID: 80053459442     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Carcillo JA, Kuch BA, Han YY et al. Mortality and functional morbidity after use of PALS/APLS by community physicians. Pediatrics 2009;124:500-508.
2. Sebat F, Musthafa AA, Johnson D et al. Effect of a rapid response system for patients in shock on time to treatment and mortality during 5 years. Crit Care Med 2007;35:2568-2575.
3. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377.
4. de Oliveira CF, de Oliveira DS, Gottschald AF et al. ACCM/PALS haemodynamic support guidelines for paediatric septic shock: an outcomes comparison with and without monitoring central venous oxygen saturation. Intensive Care Med 2008;34:1065-1075.
5. Kumar A, Roberts D, W ood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Med 2006;34:1589-1596.
6. Barie PS, W illiams MD, McCollam JS et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 2004;188:212-220.
7. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-150.
8. Lederer JA, Rodrick ML, Mannick JA. The effects of injury on the adaptive immune response. Shock 1999;11:153-159.
9. Payen D, Faivre V, Lukaszewicz AC et al. Expression of monocyte human leukocyte antigen-DR in relation with sepsis severity and plasma mediators. Minerva Anestesiol 2009;75:484-493.
10. Felmet KA, Hall MW, Clark RSB et al. Prolonged Lymphopenia, Lymphoid Depletion, and Hypoprolactinemia in Children with Nosocomial Sepsis and Multiple Organ Failure. J Immunol 2005;174:3765-3772.
11. Hotchkiss RS, Swanson PE, Freeman BD et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Critical Care Med 1999;27:1230-1251.
12. Meisel C, Schefold JC, Pschowski R et al. Granulocytemacrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-648.
13. Brady AJ, Poole-Wilson PA. Circulatory failure in septic shock. Nitric oxide: too much of a good thing? Br Heart J 1993;70:103-105.
14. Schuerholz T, Marx G. Management of sepsis. Minerva Anestesiol 2008;74:181-195.
15. Parker MM, Shelhamer JH, Natanson C et al. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987;15:923-929.
16. Munt B, Jue J, Gin K et al. Diastolic filling in human severe sepsis: an echocardiographic study. Crit Care Med 1998;26:1829-1833.
17. Court O, Kumar A, Parrillo JE et al. Clinical review: Myocardial depression in sepsis and septic shock. Crit Care 2002;6:500-508.
18. Ceneviva G, Paschall JA, Maffei F et al. Hemodynamic Support in Fluid-refractory Pediatric Septic Shock. Pediatrics 1998;102:e19.
19. Brierley J, Carcillo JA, Choong K et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009;37:666-668.
20. Toussaint S, Gerlach H. Activated Protein C for Sepsis. N Engl J Med 2009;361:2646-2652.
21. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823.
22. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
23. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care med 2008;36:296-327.
24. Nadel S, Goldstein B, W illiams MD et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369:836-843.
25. Nguyen T, Carcillo J. Bench-to-bedside review: Thrombocytopenia-associated multiple organ failure - a newly appreciated syndrome in the critically ill. Crit Care 2006; 10:235.
26. Nguyen TC, Han YY, Kiss JE et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med 2008;36:2878-2887.
27. Bongers TN, Emonts M, de Maat MP et al. Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. Thromb Haemost 2003;103:1181-1187.
28. Busund R, Koukline V, Utrobin U et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002;28:1434-1439.
29. Martin K, Borgel D, Lerolle N et al. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007;35:2375-2382.
30. Darmon M, Azoulay E, Thiery G et al. Time course of organ dysfunction in thrombotic microanguiopathy patients receiveign either plasma perfusion or plasm exchange. Crit Care Med 2006;34:2127-2133.
31. Aleem A, Al Amoudi S, Al-Mashhadani S et al. Haemophagocytic syndrome associated with hepatitis-B virus infection responding to etoposide. Clin Lab Haematol 2005;27:395-398.
32. Hsieh SM, Chang SC. Insufficient perforin expression in CD8+ T cells in response to hemagglutinin from avian influenza (H5N1) virus. 2006. J Immunol 176:4530-4533.
33. Imashuku, S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 2002;44:259-272.
34. Sato S, Kawashima H, Oshiro H et al. Virological and immunological characteristics of a 19-year-old Japanese female with fatal outcome with Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Virol 2004;31:235-238.
35. Akamatsu N, Sugawara Y, Tamura S et al. Hemophagocytic syndrome after adult-to-adult living donor liver transplantation. Transplant Proc 2006;38:1425-1428.
36. El Khoury N, Lassoued K, Pelle G et al. [Hemophagocytosis associated with an Escherichia coli sepsis: a case report]. La Revue de medecine interne 2003;24:688-691.
37. Ito S, Takada N, Ozasa A et al. Secondary hemophagocytic syndrome in a patient with methicillin-sensitive Staphylococcus Aureus bacteremia due to severe decubitus ulcer. Intern Med 2006;45:303-307.
38. Sun HY, Chen MY, Fang CT, et al. Hemophagocytic lymphohistiocytosis: an unusual initial presentation of acute HIV infection. 2004. J Acquired Immunedeficiency Syndromes 1999;37:1539-1540.
39. Castillo L, Carcillo J. Secondary hemophagocytic lymphohistiocytosis and severe sepsis/ systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 2009;10:387-392.
40. Arico M, Janka G, Fischer A et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia 1996;10:197-203.
41. Filipovich A, McClain K, Grom A. Histiocytic Disorders: Recent Insights into Pathophysiology and Practical Guidelines. Biol Blood Marrow Transplant 2009;16:S82-S89.
42. Henter JI, Horne A, Arico M et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood Cancer 2007;48:124-131.
43. Elazary AS, W olf DG, Amir G et al. Severe Epstein-Barr virus-associated hemophagocytic syndrome in six adult patients. J Clin Virol 2007;40:156-159.